KayoThera

KayoThera

PIONEERING FIRST-IN-CLASS ANTAGONISTS OF THE RETINOID NUCLEAR RECEPTOR PATHWAY FOR UNMET MEDICAL NEEDS

Private Company

Total funding raised: $30M

About

PIONEERING FIRST-IN-CLASS ANTAGONISTS OF THE RETINOID NUCLEAR RECEPTOR PATHWAY FOR UNMET MEDICAL NEEDS

Small Molecules

Funding History

2
Total raised:$30M
Series A$25M
Seed$5M